drugset / Trial / NCT02963103

A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen

NCT02963103 ↗

Phase 4 Terminated 13 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to observe and evaluate the change in renal function following conversion from cyclosporine-based immunosuppressive regimen to tacrolimus-based one.

Timeline

Start
2010-05
Primary completion
2012-10
Completion
2012-10

Outcome

Outcome not reported

Stopped (Enrollment): “Sponsor decision to terminate the study because subject enrollment was difficult.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule — Oral

Indications

No indication recorded.